SOUTH SAN FRANCISCO, Calif. CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, January 10, 2022 \u2013<\/strong> Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and support diagnostics.<\/p>\n Target enrichment panels enable more in-depth sequencing on target genes, reducing the need for comprehensive sequencing. This allows for more sensitive detection of target genetic sequences and provides higher confidence that variants will be detected, further driving the understanding of diseases and supporting healthcare professionals in providing precision medicine.<\/p>\n Labs and research institutions can purchase these ready-made panels to help accelerate their research, and also have the option of using CENTOGENE\u2019s CentoCloud\u00ae<\/a> for the identification, prioritization, and classification of human genetic variants to expedite diagnostic analysis.<\/p>\n \u201cThere are over 7,000 rare diseases impacting over 350 million patients, many of whom are not diagnosed until the late stages of the disease. Our mission is to provide data-driven, life-changing answers as early as possible to ultimately accelerate the development of treatments,\u201d said Kim Stratton, Chief Executive Officer at CENTOGENE. \u201cBy partnering with Twist to develop these custom panels, we are enabling access to diagnostics and generating novel insights for the medical community, fueled by multidimensional data from the CENTOGENE Biodatabank.\u201d<\/p>\n All three new Alliance Panels are highly curated using the CENTOGENE Biodatabank, with nearly 700,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. Identified sequences are then synthesized by Twist as biotinylated capture probes which are compatible with Twist\u2019s library preparation solution and target enrichment workflows. The panels offered through Twist will include:<\/p>\n \u201cTwist Alliance panels enable research by providing access to expert-developed panels tailored to specific research areas. CENTOGENE brings highly curated expertise and data in rare diseases, an important complement to our existing Alliance panels,\u201d said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. \u201cAs we expand our offering of Alliance panels, we believe it is critical to offer expert-developed content in an off-the-shelf format, compatible with Twist\u2019s extended custom panel offering, enabling a wider user base for these important tools.\u201d<\/p>\n For inquiries about the Twist Alliance CNTG panels please visit: https:\/\/www.twistbioscience.com\/contact<\/a>.<\/p>\n Twist Alliance CNTG Exome is designed using Twist\u2019s core exome and reference sequencing, a full mitochondrial genome and exclusive content for enhanced coverage of relevant genes and variants related to rare diseases. <\/p>\n The Twist Alliance CNTG Rare Disease Panel includes more than 2,500 relevant rare disease-associated genes and covers \u226599.5% of targeted regions, offering researchers a more lightweight tool for capturing the crucial rare disease coverage in the CNTG Exome without the full footprint. This panel can be used to detect genes associated with but not limited to rare treatable diseases, early onset childhood disorders, cardiac disorders, neurodegenerative diseases, skeletal abnormalities and metabolic disorders.<\/p>\n The Twist Alliance CNTG Hereditary Oncology Panel includes 72 selected cancer-associated genes and covers \u226599.5% of targeted regions. The panel can be used to identify genetic predisposition to hereditary tumors including breast cancer, gastrointestinal tumors, Li-Fraumeni syndrome, MEN1, MEN2, paragangliomas and others.<\/p>\n In partnership with leading research institutions from around the world, Twist has curated a collection of high-quality target enrichment panels for applications ranging from carrier screening to cancer diagnostics and whole exome sequencing. The Twist Alliance Panels combine the strengths of precise, highly uniform oligonucleotide synthesis with the specialty expertise of leading scientific research partners.<\/p>\n Well-designed, custom target enrichment panels enable increased sequencing depth on target genes while reducing overall sequencing. This allows for more sensitive detection of target sequences and higher confidence variant detection.<\/p>\n CentoCloud is a cloud-based Software as a Service (SaaS) platform specifically designed for the rapid bioinformatic analysis and interpretation of next-generation sequencing (NGS) data based on the proprietary CENTOGENE Biodatabank and external reference databases. It allows for the identification, prioritization, and classification of human genetic variants associated with genetic\/inherited diseases.<\/p>\n The fully automated bioinformatics pipeline analyzes NGS data based on CENTOGENE’s validated testing products provided by Twist Bioscience.<\/p>\n Powered by an end-to-end workflow with best-in-class bioinformatics as well as CENTOGENE’s medical reporting service, CentoCloud encompasses the latest diagnostic insights \u2013 allowing physicians around the world to provide state-of-the-art individualized patient care, no matter where they are located.<\/p>\n Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by \u201cwriting\u201d DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.<\/p>\n Obserwuj nas na \u015awiergot<\/a> | Facebook<\/a> | LinkedIn<\/a> | YouTube<\/a><\/p>\n Misj\u0105 CENTOGENE jest dostarczanie pacjentom, lekarzom i firmom farmaceutycznym opartych na danych, zmieniaj\u0105cych \u017cycie odpowiedzi na pytania dotycz\u0105ce chor\u00f3b rzadkich i neurodegeneracyjnych. Integrujemy technologie multiomiczne z baz\u0105 danych CENTOGENE Biodatabank, zapewniaj\u0105c analiz\u0119 wielowymiarow\u0105, kt\u00f3ra b\u0119dzie stanowi\u0107 punkt odniesienia dla kolejnej generacji medycyny precyzyjnej. Nasze unikalne podej\u015bcie umo\u017cliwia szybk\u0105 i wiarygodn\u0105 diagnoz\u0119 pacjent\u00f3w, wspiera lekarzy w lepszym zrozumieniu stan\u00f3w chorobowych oraz przyspiesza i ogranicza ryzyko zwi\u0105zane z odkrywaniem, rozwojem i komercjalizacj\u0105 ukierunkowanych lek\u00f3w farmaceutycznych.<\/p>\n Od momentu powstania w 2006 roku, CENTOGENE oferuje szybk\u0105 i wiarygodn\u0105 diagnostyk\u0119, buduj\u0105c sie\u0107 oko\u0142o 30 000 aktywnych lekarzy. Nasze multiomiczne laboratoria referencyjne w Niemczech, posiadaj\u0105ce certyfikaty ISO, CAP i CLIA, wykorzystuj\u0105 zestawy danych fenomicznych, genomicznych, transkryptomicznych, epigenomicznych, proteomicznych i metabolomicznych. Dane te s\u0105 gromadzone w naszym banku danych biologicznych CENTOGENE, obejmuj\u0105cym blisko 700 000 pacjent\u00f3w z ponad 120 bardzo zr\u00f3\u017cnicowanych kraj\u00f3w, z czego ponad 70% to osoby pochodzenia pozaeuropejskiego. Do tej pory bank danych biologicznych CENTOGENE przyczyni\u0142 si\u0119 do wygenerowania nowatorskich spostrze\u017ce\u0144 dla ponad 260 recenzowanych publikacji.<\/p>\n Przek\u0142adaj\u0105c nasze dane i wiedz\u0119 specjalistyczn\u0105 na konkretne wnioski, wsparli\u015bmy ponad 50 projekt\u00f3w wsp\u00f3\u0142pracy z partnerami farmaceutycznymi. Wsp\u00f3lnie przyspieszamy i ograniczamy ryzyko zwi\u0105zane z odkrywaniem, rozwojem i komercjalizacj\u0105 lek\u00f3w w zakresie bada\u0144 przesiewowych lek\u00f3w docelowych i lek\u00f3w, bada\u0144 klinicznych, dost\u0119pu do rynku i ekspansji, a tak\u017ce oferujemy licencje na CENTOGENE Biodatabank i raporty Insight Reports, aby umo\u017cliwi\u0107 \u015bwiatu wyleczenie ze wszystkich chor\u00f3b rzadkich i neurodegeneracyjnych.<\/p>\n Aby dowiedzie\u0107 si\u0119 wi\u0119cej o naszych produktach, ofercie i celach ukierunkowanych na pacjent\u00f3w, odwied\u017a stron\u0119 www.centogene.com<\/a> i \u015bled\u017a nas na LinkedIn<\/a>.<\/p>\n This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of the Twist Alliance CNTG Exome Panel to enable whole exome analysis of genetic markers relevant to rare diseases; the ability of the Twist Alliance CNTG Rare Disease Panel to offer analysis of focused rare-disease-related sequences; and the ability of the Twist Alliance CNTG Hereditary Oncology Panel to enable the detection of biomarkers that indicate a high risk of developing cancer. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience\u2019s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties relating to COVID-19; the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies, including Abveris, and to achieve expected benefits from acquisitions; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience\u2019s patents or proprietary rights; and the risk that Twist Bioscience\u2019s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience\u2019s business in general, see Twist Bioscience\u2019s risk factors set forth in Twist Bioscience\u2019s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 28, 2022 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n Niniejsza informacja prasowa zawiera \u201co\u015bwiadczenia prognostyczne\u201d w rozumieniu federalnych przepis\u00f3w dotycz\u0105cych papier\u00f3w warto\u015bciowych w Stanach Zjednoczonych. Zawarte w niej o\u015bwiadczenia, kt\u00f3re nie maj\u0105 jednoznacznie historycznego charakteru, maj\u0105 charakter prognostyczny, a s\u0142owa \u201cprzewidywa\u0107\u201d, \u201cwierzy\u0107\u201d, \u201ckontynuowa\u0107\u201d, \u201coczekiwa\u0107\u201d, \u201cszacowa\u0107\u201d, \u201czamierza\u0107\u201d, \u201cprognozowa\u0107\u201d oraz podobne wyra\u017cenia i czasowniki w czasie przysz\u0142ym lub warunkowym, takie jak \u201cb\u0119dzie\u201d, \u201cby\u0142by\u201d, \u201cpowinien\u201d, \u201cm\u00f3g\u0142by\u201d, \u201cmo\u017ce\u201d, \u201cmo\u017ce\u201d i \u201cmo\u017ce\u201d, maj\u0105 na celu identyfikacj\u0119 o\u015bwiadcze\u0144 prognostycznych. Takie o\u015bwiadczenia prognostyczne wi\u0105\u017c\u0105 si\u0119 ze znanymi i nieznanymi ryzykami, niepewno\u015bciami i innymi istotnymi czynnikami, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki, efektywno\u015b\u0107 lub osi\u0105gni\u0119cia CENTOGENE b\u0119d\u0105 istotnie r\u00f3\u017cni\u0107 si\u0119 od jakichkolwiek przysz\u0142ych wynik\u00f3w, efektywno\u015bci lub osi\u0105gni\u0119\u0107 wyra\u017conych lub dorozumianych w o\u015bwiadczeniach prognostycznych. Do takich ryzyk i niepewno\u015bci nale\u017c\u0105 m.in. negatywne warunki ekonomiczne i geopolityczne oraz niestabilno\u015b\u0107 i zmienno\u015b\u0107 na \u015bwiatowych rynkach finansowych, mo\u017cliwe zmiany w obowi\u0105zuj\u0105cych i proponowanych przepisach, regulacjach i politykach rz\u0105dowych, presja wynikaj\u0105ca ze wzrostu konkurencji i konsolidacji w naszej bran\u017cy, koszty i niepewno\u015b\u0107 zwi\u0105zana z zatwierdzeniem regulacyjnym, w tym przez Ameryka\u0144sk\u0105 Agencj\u0119 ds. \u017bywno\u015bci i Lek\u00f3w (FDA), nasze uzale\u017cnienie od stron trzecich i partner\u00f3w, w tym nasza zdolno\u015b\u0107 do zarz\u0105dzania wzrostem, realizacji strategii biznesowej i nawi\u0105zywania nowych relacji z klientami, nasza zale\u017cno\u015b\u0107 od bran\u017cy chor\u00f3b rzadkich, nasza zdolno\u015b\u0107 do zarz\u0105dzania ekspansj\u0105 mi\u0119dzynarodow\u0105, nasza zale\u017cno\u015b\u0107 od kluczowego personelu, nasza zale\u017cno\u015b\u0107 od ochrony w\u0142asno\u015bci intelektualnej, wahania naszych wynik\u00f3w operacyjnych spowodowane wp\u0142ywem kurs\u00f3w walutowych, nasza zdolno\u015b\u0107 do usprawnienia wykorzystania got\u00f3wki, nasze ci\u0105g\u0142e przestrzeganie postanowie\u0144 umownych zwi\u0105zanych z instrumentami finansowymi, nasze zapotrzebowanie na dodatkowe finansowanie lub inne czynniki. Aby uzyska\u0107 wi\u0119cej informacji na temat ryzyka i niepewno\u015bci, kt\u00f3re mog\u0105 spowodowa\u0107, \u017ce rzeczywiste wyniki b\u0119d\u0105 si\u0119 r\u00f3\u017cni\u0107 od tych wyra\u017conych w niniejszych o\u015bwiadczeniach prognostycznych, a tak\u017ce ryzyka zwi\u0105zanego z dzia\u0142alno\u015bci\u0105 CENTOGENE og\u00f3lnie, zapoznaj si\u0119 z czynnikami ryzyka CENTOGENE przedstawionymi w Formularzu 20-F z\u0142o\u017conym przez CENTOGENE 31 marca 2022 r. w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) oraz w p\u00f3\u017aniejszych dokumentach z\u0142o\u017conych w SEC. Wszelkie o\u015bwiadczenia prognostyczne zawarte w niniejszym komunikacie prasowym obowi\u0105zuj\u0105 wy\u0142\u0105cznie na dzie\u0144 jego sporz\u0105dzenia, a CENTOGENE wyra\u017anie zrzeka si\u0119 obowi\u0105zku aktualizacji jakichkolwiek o\u015bwiadcze\u0144 prognostycznych, niezale\u017cnie od tego, czy wynika to z nowych informacji, przysz\u0142ych zdarze\u0144, czy z innych przyczyn.<\/p>\n Twist Bioscience CENTOGENE <\/strong>\n
About Twist Alliance CNTG Exome<\/h3>\n
About Twist Alliance CNTG Rare Disease Panel<\/h3>\n
About Twist Alliance CNTG Hereditary Oncology Panel<\/h3>\n
About Twist Alliance Panels<\/h3>\n
About CentoCloud<\/h3>\n
About Twist Bioscience Corporation<\/h3>\n
O firmie CENTOGENE<\/h3>\n
Twist Bioscience Legal Notice Regarding Forward-Looking Statements<\/h3>\n
CENTOGENE Legal Notice Regarding Forward-Looking Statements<\/h3>\n
Kontakt<\/h5>\n
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting(at)twistbioscience(dot)com<\/a><\/p>\n
Ben Legg
Komunikacja korporacyjna
Press(at)centogene(dot)com<\/a><\/p>\n